Select Language
IL-3 R alpha
IL-3 R alpha Overview
| English Name | Interleukin-3 receptor subunit alpha | Approved Drugs | 1 |
| Drugs in Clinical Trials | 39 | Target Synonym | IL3RY，IL-3RA，CD123 Antigen，IL3RX，IL-3R Subunit Alpha，IL3R，IL-3 Receptor Subunit Alpha，IL-3 Receptor Alpha SP2 Isoform，Interleukin 3 Receptor Subunit Alpha，IL3RAY，IL-3R-Alpha，CD123，HIL-3Ra，IL3RA，Interleukin 3 Receptor， Alpha (Low Affinity)，Interleukin-3 Receptor Subunit Alpha，Interleukin-3 Receptor alpha Subunit |
| Highest Development Stage | Approved | ||
| English Name | Interleukin-3 receptor subunit alpha |
| Target Synonym | IL3RY，IL-3RA，CD123 Antigen，IL3RX，IL-3R Subunit Alpha，IL3R，IL-3 Receptor Subunit Alpha，IL-3 Receptor Alpha SP2 Isoform，Interleukin 3 Receptor Subunit Alpha，IL3RAY，IL-3R-Alpha，CD123，HIL-3Ra，IL3RA，Interleukin 3 Receptor， Alpha (Low Affinity)，Interleukin-3 Receptor Subunit Alpha，Interleukin-3 Receptor alpha Subunit |
| Approved Drugs | 1 |
| Drugs in Clinical Trials | 39 |
| Highest Development Stage | Approved |
IL-3 R alpha Product List
- Product Category
Protein (13)
- Product Status
Launched (13)
- Species
Human (10)Cynomolgus (1)Mouse (1)Canine (1)
- Tag
His Tag (7)Llama IgG Fc Tag (1)His Tag & Avi Tag (1)Fc Tag (2)Fc Tag & Avi Tag (1)Avi Tag (1)
- Conjugate
Unconjugated (6)FITC Labeled (2)Biotin-labeled (3)PE Labeled (1)APC Labeled (1)
Add to Cart
Total: 13
- 1
- 2
IL-3 R alpha Background
Interleukin 3 receptor alpha (low affinity) (IL3RA), also known as CD123 (Cluster of Differentiation 123) is a 70-kD glycoprotein member of the hematopoietin receptor superfamily. This protein associates with a beta subunit common to the receptors for IL-5 and granulocyte-macrophage colony-stimulating factor (GM-CSF) to form a high-affinity receptor for IL-3. The interleukin-3 receptor α chain (CD123) has been identified as a potential immunotherapeutic target because it is overexpressed in AML compared with normal hematopoietic stem cells.
IL-3 R alpha Synonyms
IL3R,IL3RA,IL-3Ra,IL-3R-alpha,IL3RAY,IL3RX,IL3RY,CD123 antigen,CD123,hIL3Ra,hIL-3Ra,MGC34174,IL-3 R alpha
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Talacotuzumab | CSL-362; JNJ-473; CSL-362-AML; JNJ-56022473; IL-13 MAb-CSL | Phase 2 Clinical | Csl Ltd | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| Vibecotamab | XmAb-14045 | Phase 2 Clinical | Xencor Inc | Leukemia, Myeloid; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
| Pivekimab sunirine | IMGN-632 | Phase 2 Clinical | Immunogen Inc | Leukemia; Myelodysplastic Syndromes; Myeloproliferative Disorders; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute; Myelodysplastic-Myeloproliferative Diseases | Details |
| CD123 CAR-T cell therapy(Chongqing Precision Biotechnology) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Leukemia; Leukemia, Myeloid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details | |
| Anti-CD123 CAR T-cell therapy (Southwest Hospital) | Phase 2 Clinical | The Southwest Hospital of AMU | Leukemia, Myeloid | Details | |
| CAR-T Cells Targeting CD33/CD123 therapy(Essen Biotech) | BAH244; BAH-244 | Phase 2 Clinical | Essen Biotech | Leukemia, Myeloid, Acute | Details |
| AZD-9829 | AZD9829; AZD-9829 | Phase 2 Clinical | Astrazeneca Plc | Hematologic Neoplasms; Hematologic Diseases; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| Anti Tim-3/CD123 CAR-T Cell Therapy(Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu), The Affiliated Hospital Of Xuzhou Medical University | Leukemia, Myeloid, Acute | Details | |
| MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
| Mipletamig | APVO-436; APVO436 | Phase 2 Clinical | Aptevo | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| SAR-443579 | SAR-443579; SAR443579; SAR'579; IPH6101; IPH-6101 | Phase 2 Clinical | Sanofi | Hematologic Diseases; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Acute | Details |
| Anti-CD123 CAR T-cell therapy (University of Pennsylvania/Novartis) | JEZ-567 | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Leukemia, Myeloid, Acute | Details |
| Flotetuzumab | S-80880; MGD-006; RES-234 | Phase 1 Clinical | Macrogenics Inc | Hematologic Neoplasms; Leukemia; Leukemia, Myelogenous, Chronic; Leukemia, Hairy Cell; Mastocytosis, Systemic; Hodgkin Disease; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute | Details |
| UCART-123 | UCART-123; UCART-123v1.2 | Phase 1 Clinical | Cellectis Sa | Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details |
| JNJ-63709178 | JNJ-9178; CNTO-9958; JNJ-63709178 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine, Genmab A/S | Leukemia, Myeloid, Acute | Details |
| Anti-CD123 CAR T cell therapy (Shanghai GeneChem) | Phase 1 Clinical | Shanghai Genechem Co Ltd | Leukemia, Myeloid, Acute | Details | |
| IM-23 (Beijing Immunochina Medical Science and Technology) | IM-23; IM-23 CAR-T | Phase 1 Clinical | Beijing Immunochina Medical Science & Technology Co Ltd | Leukemia, Myeloid, Acute | Details |
| Anti-CD123 CAR T-cell therapy (Nanjing Legend Biotech) | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details | |
| MB-102 (Mustang Bio) | MB-102 | Phase 1 Clinical | Mustang Bio Inc, City Of Hope National Medical Center | Neoplasm, Residual; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute | Details |
| UniCAR-T-CD-123 | UniCAR-T-CD123; AVC-101 | Phase 1 Clinical | AvenCell Therapeutics Inc, AvenCell Europe GmbH | Leukemia, Myeloid, Acute | Details |
| ACLX-002 | ACLX-002 | Phase 1 Clinical | Arcellx Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| MGD-024 | MGD-024 | Phase 1 Clinical | Macrogenics Inc | Leukemia, Myelogenous, Chronic; Leukemia, Hairy Cell; Hodgkin Disease; Myelodysplastic Syndromes; Neoplasms; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, B-Cell; Leukemia, Myeloid, Acute | Details |
| AFM-28 | AFM-28 | Phase 1 Clinical | Affimed | Leukemia, Promyelocytic, Acute; Neoplasms; Leukemia, Myeloid, Acute | Details |
| VIP943 | BAY-943; VIP-943 | Phase 1 Clinical | Bayer AG | Myelodysplastic Syndromes; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
| Donor-derived CD123-CD16 bispecific antibody-modified NK cells therapy(Chinese PLA General Hospital) | Phase 1 Clinical | Pla General Hospital | Leukemia, Myeloid, Acute | Details | |
| Autologous CAR123 T lymphocytes cell tharapy(Institute of Hematology and Blood Transfusion, Czech Republic) | Phase 1 Clinical | Institute of Hematology and Blood Transfusion, Czech Republic | Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details | |
| Anti-CD123 CAR NK cells therapy(Chongqing Precision Biotechnology) | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Neoplasms, Plasma Cell; Leukemia, Myeloid, Acute | Details | |
| CD123 CAR-NK cell therapy(Beijing JD Biotech) | JD123; JD-123 | Phase 1 Clinical | Beijing JD Biotech Co Ltd | Leukemia, Myeloid, Acute | Details |
| Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
| AVC-201 | AVC-201; Allo-RevCAR01-T-CD123 | Phase 1 Clinical | AvenCell Europe GmbH | Leukemia, Myeloid, Acute | Details |
| CD123-CAR T cells(St Jude Children's Research Hospital) | Phase 1 Clinical | St. Jude Children'S Research Hospital | Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| LAVA-1266 | LAVA-1266; LAVA1266 | Phase 1 Clinical | Lava Therapeutics NV | Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details |
| Allogenic CD123-CAR-NK Cells therapy(JD Biotech) | JD023 | Phase 1 Clinical | Beijing JD Biotech Co Ltd, Chinese Academy Of Military Medical Sciences | Leukemia, Myeloid, Acute | Details |
| BYON-4413 | BYON-4413 | Phase 1 Clinical | Byondis Bv | Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details |
| GR-1901 | GR1901; GR-1901 | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | |
| SQZ-622(Novartis Pharma) | SQZ-622 | Phase 1 Clinical | Novartis Pharma Ag | Leukemia, Myeloid, Acute | Details |
| UniCAR02-T | UniCAR02-T | Phase 1 Clinical | Cellex Patient Treatment Gmbh | Kidney Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| IL3 CAR T-cell therapy (Yake Biotechnology) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
| Anti-CD123 chimeric antigen receptor T cell therapy (Yake Biotechnology) | Clinical | Shanghai YaKe Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tagraxofusp | SL-401; DTIL-3; DT388 IL3 | Approved | Texas A&M University Development Foundation | Elzonris | United States | Blastic Plasmacytoid Dendritic Cell Neoplasm | Stemline Therapeutics Inc | 2018-12-21 | Leukemia; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Blastic Plasmacytoid Dendritic Cell Neoplasm; Multiple Myeloma; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Lymphoma | Details |
Product Reviews
C***e2023-05-23
0People LikeWe used Biotinylated Human IL-3 R alpha / CD123 Protein, Fc,Avitag™ (MALS verified) for a viral titer assay with Jurkat cells and received excellent results. We had a great experience ordering from the Acro biosystems website, which was easy to navigate. The reconstitution directions were very helpful and clear and each vial lasted for several experiments. The shipping was very quick and we look forward to ordering more products from Acro.- Y***a2022-05-10 0People LikeWe received the product at a reasonably fast speed. We used this product in ELISA. The product is robust and of good quality. The characterization information was accurate, reliable, and valuable for further calculations.
- E***z2022-04-22 0People LikeAfter struggling to express large quantities of this protein in-house, we ordered this product and used it as the bait in our antibody discovery pipeline and found to to be extremely high quality. We used this product in ELISA as well as BLI, and generated reproducible results. In addition, we found the batch biotinylation information to be accurate which was helpful for calculating inputs for experiments.
Load More
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland